Table 5.
Risk factors for SECOND MONTH SMEAR NEGATIVATION among pulmonary tuberculosis patients from October 2009 to September 2010 (hierarchized model)
| Characteristics | % | OR | 95% CI | adj OR | 95% CI |
|---|---|---|---|---|---|
| FDC-RHZE | |||||
| No | 66.4 | 1 | 1 | ||
| Yes | 33.6 | 1.104 | 0.932 - 1.307 | 1.164 | 0.999 - 1.372 |
| DOT | |||||
| No | 75.9 | 1 | 1 | ||
| Yes | 24.1 | 1.450 | 1.208 - 1.739 | 1.373 | 1.137 - 1.658 |
| The unit assists over 125 cases yearly | |||||
| No | 50.1 | 1 | 1 | ||
| Yes | 49.9 | 0.782 | 0.663 - 0.922 | 0.817 | 0.686 - 0.974 |
| The unit has exclusively primary care | |||||
| No | 84.4 | 1 | 1 | ||
| Yes | 15.6 | 1.289 | 1.065 - 1.559 | 1.336 | 1.099 - 2.126 |
Bold numbers are statistically significant findings. FDC = fixed-dose combination; R = rifampin; H = isoniazid; Z = pyrazinamide; E = ethambutol, DOT = directly observed treatment; OR = odds ratio; adjOR = adjusted odds ration; CI = confidence interval.